Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,182

Document Document Title
WO/2017/199033A1
The invention relates to compounds of general formula (I): wherein: R1,R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditio...  
WO/2017/199039A1
The invention relates to a process for preparing a compound of general formula (Ia): wherein R2, Y, R4 and R5 are as defined herein. The invention also relates to certain compounds per se. The compounds are intermediates in the synthesis...  
WO/2017/148977A1
This invention concerns Selective Progesterone Receptor Modulators (SPRM) in a prodrug form as well as their application in therapy. (3α, 11β,17β)-1 1-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9- diene-3,17-diol (Compoun...  
WO/2017/129125A1
The present invention relates to a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof, and relates to applications thereof in the preparation of drugs for treating FXR related diseases.  
WO/2017/112904A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/112902A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/079062A1
The present application relates to a method of preparing a bile acid derivative, or a pharmaceutical acceptable salt, solvate, or amino acid conjugate thereof, comprising direct alkylation at the C-6 position of KLCA.  
WO/2017/064724A1
The present invention relates to a simple and commercially feasible preparation of high purity Fulvestrant. The present invention also provides improved process for the preparation of Fulvestrant intermediates.  
WO/2017/053826A1
The present invention relates to methods and novel intermediates useful in the preparation of a compound or a pharmaceutically acceptable salt thereof. An objective of the present invention is to provide methods of preparing bile acid de...  
WO/2016/191872A1
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also...  
WO/2016/173397A1
The present invention relates to a cholic acid derivative, and a preparation method and a medical use thereof. In particular, the present invention relates to a cholic acid derivative with the structure of formula (I), a stereoisomer, or...  
WO/2016/173524A1
Disclosed in the present application are the compounds as shown in formulae I, II, III, IV or V, tautomers thereof, stereoisomers thereof or pharmaceutically acceptable salts thereof, and also disclosed is the use thereof in preparing dr...  
WO/2016/120894A1
The present invention relates to crystalline forms of S-[4-(3-fluoro-3-methylbutyryloxy)but-2- ynyl] 6α,9α-difluoro- 17α-(furan-2-yl)carbonyloxy- 11β-hydroxy- 16α-methyl-3-oxoandrosta- 1,4- diene-17β-carbofhioate, an anti-inflammat...  
WO/2016/081029A1
What are described are compounds of formulas Π, HI, IV, and V. The compound of formula II consists of a compound in which R1 and R2 are both a linear alkyl consisting of 1 to 12 carbons, an alkenyl or alkynyl consisting of 2 to 12 carbo...  
WO/2016/054280A1
A method of preparing a thioic acid intermediate of fluticasone propionate includes: treating a 17β-[(N,N-dimethyl carbamoyl)thio]carbonyl compound in a solution including an alcohol and an alkali metal hydroxide, an alkaline-earth meta...  
WO/2016/037956A1
The invention relates to AKR1C3 inhibitors of formula (I) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or...  
WO/2016/029888A1
The present invention provides amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use as medicaments for treating neuropsychiatric disorders associated with an ...  
WO/2016/023082A1
H:\dar\Interwoven\NRPortbl\DCC\DAR\8230712_1.doc-12/08/2015 Abstract The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymp...  
WO/2016/012982A1
The present invention relates to a pharmaceutical combination comprising a PI3K/m TOR inhibitor of Formula (I) (as described herein) or a pharmaceutically acceptable salt or a solvate thereof; and one or more anti-cancer agent selected f...  
WO/2015/188791A1
Disclosed is a method for preparing a Zytiga intermediate. The intermediate is trifluoromethanesulfonate of dehydroepiandrosterone acetate and has a chemical structure represented by formula (II). In the method, dehydroepiandrosterone ac...  
WO/2015/181116A1
A process for preparing compounds of formula (I), or a salt, solvate or stereoisomer thereof, including Fulvestrant, which process comprises free radical to a compound of formula (III), or a salt, solvate or stereoisomer thereof. The inv...  
WO/2015/181275A1
13073PTWO 56 ABSTRACT The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases. 5  
WO/2015/181275A8
The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.  
WO/2015/177469A1
The present invention relates to chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, the invention enables improvement of muscular quality in sarcopenic mammals ...  
WO/2015/170341A1
The invention discloses an improved cost-effective process for preparation of 7-Dehydrocholesterol of formula I with good yield and purity, comprising:a) epimerizing 7(alpha+beta) bromo protected cholesterol in presence of tetrabutyl amm...  
WO/2015/118474A1
The present disclosure relates to an improved process for the purification of fluticasone propionate by: a) dissolving fluticasone propionate in a ketone solvent to produce a mixture, b) heating the mixture slowly for 1-2 hours to get a ...  
WO/2015/114518A2
Disclosed is a process for the preparation of abiraterone and abiraterone acetate with high yields and purity. A key element of the method is the isolation of a crystalline intermediate that makes the process particularly suitable for im...  
WO/2015/114518A3
Disclosed is a process for the preparation of abiraterone and abiraterone acetate with high yields and purity. A key element of the method is the isolation of a crystalline intermediate that makes the process particularly suitable for im...  
WO/2015/074085A1
What is described is a compound of formula (I), wherein R1 and R2 are the same or different, each a linear or branched alkyl with 1-9 carbons, or an alkenyl or alkynyl with 2 to 11 carbon atoms; L1 and L2 are the same or different, each ...  
WO/2015/014686A1
The present invention relates to a novel process for the synthesis of abiraterone and in particular abiraterone acetate, a compound of formula (I) reported below: having pharmacological activity suitable for slowing down the progression ...  
WO/2015/015246A1
The present invention relates to a novel process for the synthesis of abiraterone, and in particular of abiraterone acetate, compound of formula (I) reported below: N O (I) which has pharmacological activity useful tor slowing down the p...  
WO/2014/207567A3
The present invention provides intermediates for preparing abiraterone, and processes for preparing abiraterone and intermediates thereof. The intermediates include a compound of formula (IV), wherein R represents a hydroxy-protecting gr...  
WO/2014/192027A1
The present invention relates to methods of treatment of inflammatory conditions using S -[4-(3-fluoro-3-methylbutyryloxy)-but-2-ynyl]6α,9α-difluor o-17α-(furan-2-yl)carbonyloxy-11β-hydroxy-16α-methyl-3-ox oandrosta-1,4-diene-17β-c...  
WO/2014/184271A1
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1 is a hydroxy group and R2, R3, R4, R5, and R6 are as described herein. The present inven...  
WO/2014/104400A1
Provided is an actinic-ray- or radiation-sensitive resin composition including a resin (A) and any of compounds (B) of general formula (I) below. (In general formula (I), Rf represents a fluorine atom or a monovalent organic group contai...  
WO/2014/079801A1
The invention relates to a method for increasing the particle size of crystalline active micro-particles comprising the following steps: (a) a first suspension consisting of crystalline active micro-particles with a first d50value of 0.5...  
WO/2014/075978A1
The present invention relates to a process for making abiraterone-3-acetate of formula (1) starting from dehydroepiandrosterone-3-acetate of formula (2) by converting it into the triflate of formula (5) in an inert solvent in the presenc...  
WO/2014/071984A1
The present invention relates to an improved process for making abiraterone-3-acetate of formula (1) starting from dehydroepiandrosterone-3-acetate (DHEA) of formula (2). In particular, it relates to an improved process of converting the...  
WO/2014/064712A3
The present invention relates to an improved process for the preparation of Fulvestrant (I). Also, provided is novel intermediate of Fulvestrant and a process for the preparation of the same.  
WO/2013/169647A1
The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods f...  
WO/2013/154752A1
5-cholesten, 3β, 25-diol, disulfate (25HCDS) has been found to be an authentic PPARϒ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflam...  
WO/2013/056181A1
Provided herein are 3,3-disubstituted 19-nor- steroidal compounds according to Formula (I) and (III): where R1,R2, R3, R3', R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful fo...  
WO/2013/036835A1
Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L1, L2, L3, X1, X2, Y, Rz4, Rz5, Rz6, n, R1, R2, R3a, R3b, R4a...  
WO/2012/160338A1
The present invention relates to a method of preparing an organic biologically active compound of formula (I), wherein R1, R2, R3, R4,. X1, X2 and X3 are as defined in the specification, to certain novel intermediates obtainable from suc...  
WO/2012/079275A1
Provided is a method for preparing fluticasone furoate (fluoromethyl 6α,9α-difluoro-11β-hydroxy-16a-methyl-17α-[(2-furoyl)oxy ]-3-one androsta-1,4-diene-17β-thiocarboxylate) represented by Formula I. The method comprises: 1) forming...  
WO/2012/056201A3
The invention provides electrophilic monohalomethylating reagents, methods for their preparation and methods for preparation of monohalomethylated biologically active compounds using such reagents. Typical monohalomethyl groups transferr...  
WO/2012/056201A2
The invention provides a compound of formula A, B, C or D, methods for making them, intermediates therefor, and their use in making organic biologically active compounds: (Formula (A)). Wherein: • X = F, CI, Br, I, sulfonate esters, ph...  
WO/2012/029077A3
The present invention relates to an improved process for the preparation of substituted Fluticasone derivatives. The invention also reveals the processes for the purification of Fluticasones and related intermediates to provide the highl...  
WO/2011/151625A1
The present invention describes processes for the preparation of, monofluoromethylated organic biologically active compounds, such as Fluticasone Propionate and Fluticasone Furoate, in the presence of fluorodecarboxylating reagents such ...  
WO/2011/151624A8
The present invention describes a process for the preparation of monofluoromethylated organic biologically active compounds using monofluoromethylated reagents. Fluticasone Propionate and Fluticasone Furoate can be prepared using, for ex...  

Matches 1 - 50 out of 1,182